Press release - 20/06/2023 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance in glioblastoma. A first data readout is expected in the second half of 2024.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
Dossier - 20/11/2025 Prevention as the key to health Many serious illnesses can be prevented or at least mitigated through healthy lifestyles and early diagnosis. However, effective prevention requires holistic approaches at all levels of healthcare and the reinforcement of individual health literacy.https://www.gesundheitsindustrie-bw.de/en/article/dossier/prevention-key-health
FlareOn Biotech - fluorescence-guided tumour margin detection - 01/07/2026 A sensor designed to visualise residual tumour tissue during surgery In order to safely remove tumours in the head and neck region, surgeons must be able to reliably distinguish diseased tissue from healthy tissue. FlareOn Biotech, a start-up based in Frickenhausen, has developed a biochemical sensor capable of visualising tumour cells in tissue samples directly in the operating theatre within just ten minutes. The company is now seeking partners to help bring its diagnostic platform to market.https://www.gesundheitsindustrie-bw.de/en/article/news/sensor-designed-visualise-residual-tumour-tissue-during-surgery
Press release - 11/05/2026 What Really Helps People Quit Smoking Whether people try to quit smoking depends heavily on public health policies in their respective countries – whether they are successful, however, depends primarily on their personal environment and behavior. This was the finding of researchers from the German Cancer Research Center (DKFZ) in an international study.https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-really-helps-people-quit-smoking
Press release - 05/09/2025 After EMBL: Umlaut.bio and its potential role in drug development Alumnus Bastian Linder discusses the origin of this start-up and how a tRNA mechanism is helping scientists understand the importance and use of various RNA modifications as they pertain to disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-embl-umlautbio-and-its-potential-role-drug-development
Press release - 29/11/2023 Tracing the Evolution of the Cerebellum Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum
Press release - 19/05/2025 How the Epstein-Barr virus promotes its spread in the body Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
Rewriting the transcript to heal diseases - 29/01/2026 Therapy involving the umlauts of the genetic alphabet tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.https://www.gesundheitsindustrie-bw.de/en/article/news/therapy-involving-umlauts-genetic-alphabet
Press release - 21/05/2025 How aging changes the blood system in humans and mice The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
Press release - 14/03/2024 Planned NMI spin-off: immuneAdvice successful in start-up competition Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/geplante-nmi-ausgruendung-immuneadvice-bei-startup-wettbewerb-erfolgreich
Press release - 05/11/2024 How biomedical innovation improves preclinical research 3D tumor models, simulations of drug responses or plant stems used for testing heart stents: the 3R-BioMedicUS center at the University of Stuttgart is developing innovative biomedical approaches to improve preclinical studies, to be seen in the new video.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-biomedical-innovation-improves-preclinical-research
Press release - 17/01/2024 Immatics Announces Pricing of $175 Million Public Offering Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering
Press release - 13/03/2023 AI and multispectral imaging facilitate keyhole surgery How can camera images be used during minimally invasive surgeries to assess whether the operated organ is sufficiently perfused with blood? Scientists from the German Cancer Research Center (DKFZ) and the Städtisches Klinikum Karlsruhe have now succeeded in automatic monitoring of ischemia during a kidney surgery using only the optical properties of the tissue and not relying on injection of contrast agent. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ki-und-moderne-bildgebung-erleichtern-schluesselloch-chirurgie
Press release - 16/09/2021 Organ twin: a “flight simulator” for surgeons Cyber Valley researchers have created medical educational tools that could potentially train the surgeons of the future, much like flight simulators train pilots. The team developed a range of artificial organ phantoms to serve as training platforms for surgeons. Thanks to the structured data of experienced medical professionals, a quantitative and objective assessment of a trainee’s skills can be assessed in real time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/organ-twin-flight-simulator-surgeons
Press release - 06/03/2025 NMI TT in Reutlingen and Düsseldorf University Women's Hospital develop high-precision method for analyzing individual circulating tumor cells Researchers have developed a new method that enables a more precise analysis of individual tumor cells circulating in the blood. This allows not only the previously possible genomic investigation of such tumor cells, but also the focused analysis of single-cell signaling pathways at the functional protein level. The combined analysis of the mutated genome and signaling proteins opens up new avenues for more targeted treatment methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-reutlingen-and-duesseldorf-university-womens-hospital-develop-high-precision-method-analyzing-individual-circulating-tumo
Press release - 19/03/2025 Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
Press release - 22/03/2024 New Emmy Noether junior research group for biological data science An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-biological-data-science
Press release - 27/03/2024 Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-granted-orphan-drug-designation-fda-its-proprietary-atac-candidate-hdp-101
The Baden-Württemberg healthcare industry The biotechnology sector Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.https://www.gesundheitsindustrie-bw.de/en/location/biotech
Press release - 26/05/2026 How blood stem cells diversify Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in “Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-stem-cells-diversify
Press release - 18/01/2021 How a protein variant could explain resistance to sleeping sickness drug A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
Press release - 24/05/2024 Research Training Group on Cancer Surgery: German Research Foundation approves second funding period Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period
Dossier - 09/02/2015 Chemical tools for biological applications The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology. https://www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Dossier - 09/09/2013 New trends in the field of immunology B- and T- lymphocytes along with macrophages have long been regarded as the most important cells of the human immune system and have been a major focus of research. This has now changed and it is now the dendritic cells that are regarded as the major components of the adaptive immune system. Research into innate immune defence mechanisms has become more important due to the discovery of the role of Toll-like receptors as first-line of defence.https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-trends-in-the-field-of-immunology
Press release - 13/12/2024 Schizophrenia: NMI observes processes in nerve cells Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells